Precede Biosciences Launches Precede Bio Insight at AACR 2026
Precede Biosciences has launched Precede Bio Insight™, an innovative genome-wide liquid biopsy product that decodes transcriptional biology from cell-free DNA. This launch, highlighted at the AACR 2026 Annual Meeting, allows for real-time insights into tumor biology and patient treatment selection from just 1 mL of plasma, enhancing precision medicine in cancer treatments.
BOSTON, April 21, 2026 (GLOBE NEWSWIRE) — Precede Biosciences, a company powering next-generation precision medicine through its comprehensive epigenomic liquid biopsy platform, today announced the launch of Precede Bio Insight™ and the presentation of new data at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17–22 in San Diego, California.